/EVLO
EVLO Stock - Evelo Biosciences, Inc.
Healthcare|BiotechnologyOTC
$0.00+400.00%
+$0.00 (+400.00%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.69
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.92
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EVLO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.70
52W High$0.00
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-108,466,000 | $-115,396,000 | $-91,886,000 | $-86,357,000 | $-58,103,000 |
| Net Income | $-114,527,000 | $-122,176,000 | $-93,666,000 | $-85,662,000 | $-53,854,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-26.28 | $-46.18 | $-47.45 | $-53.49 | $-49.25 |
Company Overview
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
EVLOBeat Rate
58%
Last 12 quarters
Avg Surprise
-222.5%
EPS vs Estimate
Beats / Misses
7/5
Last 12 quarters
Latest EPS
$-0.66
Q4 2023
EPS Surprise History
Q1 22
+11.5%
$-10.80vs$-12.20
Q2 22
+3.4%
$-11.20vs$-11.60
Q3 22
+28.6%
$-8.00vs$-11.20
Q4 22
+15.2%
$-5.60vs$-6.60
Q1 23
+30.0%
$-4.20vs$-6.00
Q2 23
-2775.0%
$-4.60vs$-0.16
Q3 23
+18.0%
$-3.55vs$-4.33
Q4 23
+50.7%
$-0.66vs$-1.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 24, 2025 | — | — | — | — |
Q2 2025 | Jun 4, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Dec 26, 2024 | — | — | — | — |
Q3 2024 | Sep 27, 2024 | — | — | — | — |
Q2 2024 | Jun 7, 2024 | — | — | — | — |
Q1 2024 | Jan 26, 2024 | — | — | — | — |
Q4 2023 | Nov 9, 2023 | $-1.34 | $-0.66 | +50.7% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-4.33 | $-3.55 | +18.0% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.16 | $-4.60 | -2775.0% | ✗ MISS |
Q1 2023 | Mar 16, 2023 | $-6.00 | $-4.20 | +30.0% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-6.60 | $-5.60 | +15.2% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-11.20 | $-8.00 | +28.6% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-11.60 | $-11.20 | +3.4% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-12.20 | $-10.80 | +11.5% | ✓ BEAT |
Q4 2021 | Oct 28, 2021 | $-11.40 | $-12.60 | -10.5% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-10.80 | $-11.80 | -9.3% | ✗ MISS |
Q2 2021 | Apr 29, 2021 | $-10.60 | $-11.00 | -3.8% | ✗ MISS |
Q1 2021 | Mar 9, 2021 | $-9.60 | $-12.40 | -29.2% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about EVLO
What is EVLO's current stock price?
Evelo Biosciences, Inc. (EVLO) is currently trading at $0.00 per share. The stock has moved +400.00% today.
What is the analyst price target for EVLO?
No analyst price targets are currently available for this stock.
What sector is Evelo Biosciences, Inc. in?
Evelo Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is EVLO's market cap?
Evelo Biosciences, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does EVLO pay dividends?
No, Evelo Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARDS
Aridis Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
BTAX
Biostax Corp.
$0.00
Mkt Cap: $0.0B
HSTC
HST Global, Inc.
$0.99
Mkt Cap: $0.0B
ICCT
iCoreConnect Inc.
$0.00
Mkt Cap: $0.0B
INFIQ
Infinity Pharmaceuticals, Inc.
$0.00
Mkt Cap: $0.0B
LIFS
Life Stem Genetics Inc.
$0.00
Mkt Cap: $0.0B
PXMD
PaxMedica, Inc. Common Stock
$0.00
Mkt Cap: $0.0B
SECI
Sector 10, Inc.
$0.00
Mkt Cap: $0.0B
STAB
Statera Biopharma, Inc.
$0.00
Mkt Cap: $0.0B
TRVN
Trevena, Inc.
$0.01
Mkt Cap: $0.0B
Explore stocks similar to EVLO for comparison